|1.||Laurenza, Antonio: 17 articles (11/2015 - 08/2012)|
|2.||Yang, Haichen: 15 articles (08/2015 - 08/2012)|
|3.||Squillacote, David: 9 articles (07/2014 - 05/2010)|
|4.||Williams, Betsy: 8 articles (08/2015 - 02/2015)|
|5.||Krauss, Gregory L: 7 articles (09/2015 - 08/2012)|
|6.||Steinhoff, Bernhard J: 7 articles (05/2015 - 01/2013)|
|7.||Zhu, Jin: 6 articles (07/2015 - 01/2013)|
|8.||Kumar, Dinesh: 6 articles (07/2015 - 02/2012)|
|9.||Fain, Randi: 5 articles (08/2015 - 06/2014)|
|10.||Ferry, Jim: 5 articles (08/2015 - 08/2013)|
09/01/2015 - "In phase III trials of 17 or 19 weeks' duration, add-on perampanel ≤12 mg/day significantly improved seizure control in patients aged ≥12 years who were experiencing either primary GTCS or POS (with or without secondary generalization), despite ongoing treatment with stable dosages of one to three AEDs. "
01/01/2013 - "Overall, these studies form a solid evidence base to support the efficacy of adjunctive perampanel in the treatment of refractory partial-onset seizures."
01/01/2013 - "More perampanel-treated patients had ≥ 75% reductions in SG seizure frequency, and seizure-freedom rates improved, compared with placebo. "
01/01/2013 - "This phase III trial demonstrated that adjunctive treatment with once-daily perampanel at 8 mg and 12 mg was effective in improving seizure control in patients 12 years and older with refractory partial-onset seizures. "
08/07/2012 - "This study provides Class I evidence that once-daily 8 and 12 mg doses of adjunctive perampanel are effective in patients with uncontrolled partial-onset seizures."
04/01/2014 - "This, coupled with the identification of an optimal dosing strategy for individual patients, may help to maximize the utility of perampanel in the treatment of epilepsy."
04/01/2013 - "Novel treatment options for epilepsy: focus on perampanel."
12/01/2012 - "Epilepsy: perampanel-new promise for refractory epilepsy?"
11/01/2015 - "Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes."
05/01/2015 - "According to the results of three pivotal placebo-controlled, double-blind phase III trials that investigated perampanel as an adjunctive AED in adult and adolescent patients from age 12 years who had ongoing focal epileptic seizures despite receiving one to three AEDs, perampanel has been widely licensed and introduced. "
|3.||Status Epilepticus (Complex Partial Status Epilepticus)
04/01/2015 - "We provide some evidence concerning the efficacy of perampanel (PER) in refractory status epilepticus (SE). "
04/01/2015 - "Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus."
08/01/2015 - "Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit."
09/01/2014 - "Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus."
03/01/2014 - "The physiological and pathological role of AMPAR in the CNS and the development of AMPAR antagonists have recently gained attention considering their recent involvement in status epilepticus and the marketing of perampanel. "
|4.||Parkinson Disease (Parkinson's Disease)
05/15/2010 - "Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study."
02/01/2012 - "Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. "
01/01/2012 - "Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone."
02/01/2012 - "Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease."
05/15/2010 - "Perampanel, a novel, noncompetitive, selective AMPA-receptor antagonist demonstrated evidence of efficacy in reducing motor symptoms in animal models of Parkinson's disease (PD). "
01/01/2014 - "Perampanel is the first potentially efficacious treatment for Lafora disease. "
01/01/2013 - "Adjunctive therapy with perampanel was started in this patient with advanced Lafora disease and was titrated up to 8 mg/day. "
01/01/2013 - "The aim of this report is to provide initial evidence that add-on treatment with perampanel might be highly effective in progressive myoclonic epilepsy such as Lafora disease. "
01/01/2013 - "Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease)."
01/01/2014 - "We report a patient with Lafora disease who experienced a dramatic amelioration in her seizure frequency as well as the associated neurological and cognitive dysfunction following initiation of treatment with perampanel administered as monotherapy. "
|1.||AMPA Receptors (AMPA Receptor)
|4.||Immunoglobulin E (IgE)
|7.||GYKI 53405 (talampanel)
|8.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|9.||Anticonvulsants (Antiepileptic Drugs)
|10.||Glutamate Receptors (Glutamate Receptor)
|1.||Electric Stimulation Therapy (Electrotherapy)
|2.||Renal Dialysis (Hemodialysis)